Market Research Report

A quick peek into the report

Europe MRD Testing Market - A Country Analysis

Focus on End User and Country Analysis - Analysis and Forecast, 2023-2033

 
Some Faq's

Frequently Asked Questions

Companies manufacturing and distributing different test, assays and panels used for MRD testing in leukemia, lymphoma, and solid tumors, as well as startups looking to enter the MRD market, should buy this report.

The Europe MRD testing market is projected to reach $1,744.0 million by 2033 from $424.0 million in 2023, growing at a CAGR of 15.19% during the forecast period 2023-2033. 

MRD (Minimal Residual Disease) tests are medical assessments used to detect and measure the presence of residual cancer cells in a patient's body after treatment. These tests are crucial in evaluating the effectiveness of cancer treatments and determining the risk of disease recurrence. They help guide further treatment decisions and monitor a patient's progress.

MRD (Minimal Residual Disease) is typically tested using advanced laboratory techniques such as polymerase chain reaction (PCR), flow cytometry, or next-generation sequencing (NGS). These methods analyze a patient's bone marrow or peripheral blood samples to detect and quantify residual cancer cells at extremely low levels, providing valuable information about treatment response and risk of recurrence.

The commonly accepted MRD positivity threshold is 0.01%, primarily due to the standard limit of detection for routine flow cytometry and molecular tests. However, with PCR, it is feasible to routinely achieve a higher sensitivity of 0.001% in clinical samples, surpassing the usual threshold.

Similar Product

You may also like

MRD Testing Market - Global and Regional Analysis
Published Year: 2024

MRD Testing Market - Global and Regional Analysis: Focus on Technology, Target Detection, End User a

The MRD testing market was valued at $1.47 billion in 2022 and is expected to reach $6.67...